Nexentis Technologies Inc. (NASDAQ:NXTS) saw its shares increase roughly 10% on Tuesday following word that its subsidiary, MitoCareX Bio Ltd., obtained trademark registration in the United States for its algorithm platform, MITOLINE, from the United States Patent and Trademark Office.
MITOLINE is described by the company as a proprietary sequence analysis and alignment algorithm developed to ready mitochondrial carrier proteins from the SLC25 family for 3D homology modeling. The platform is intended to address a noted absence of solved three-dimensional structures for the majority of human mitochondrial carriers, an obstacle the company says hampers mitochondrial drug discovery.
The algorithm functions by systematically aligning and annotating key amino acid sequences and specific residues. That annotated alignment then enables researchers to produce 3D comparative models for target mitochondrial carriers using structural modeling tools, according to the company statement.
MitoCareX is focused on advancing therapies that target proteins in the mitochondrial SLC25 carrier family, with an emphasis on cancers and inflammatory metabolic diseases. The subsidiary has assembled a cloud-based discovery engine designed to support the identification of small molecule scaffolds aimed at hard-to-treat cancers and inflammatory metabolic conditions.
In commenting on the trademark milestone, David Palach, Chief Executive Officer of Nexentis Technologies, said: "Securing U.S. trademark registration for MITOLINE is an important step in strengthening the distinct identity of our discovery engine as we scale MitoCareX within Nexentis."
Beyond its drug discovery activities, Nexentis Technologies also invests in solar energy assets under an RTB - Ready to Build - business model. MitoCareX operates as a wholly owned subsidiary of Nexentis.
The trademark registration and the company's description of MITOLINE underline MitoCareX's technical approach: preparing SLC25 family carrier proteins for three-dimensional comparative modeling by aligning and annotating amino acid sequences and residues, then using structural modeling tools to generate 3D models. According to the company, this workflow aims to mitigate the current lack of solved 3D structures for most human mitochondrial carriers, which it identifies as a bottleneck in mitochondrial-targeted drug discovery.
Context and implications
- Market reaction: NXTS shares gained roughly 10% after the trademark approval announcement.
- Technical focus: MITOLINE centers on sequence alignment and annotation for SLC25 mitochondrial carrier proteins to enable 3D homology modeling.
- Business scope: MitoCareX is pursuing small molecule discovery for cancers and inflammatory metabolic diseases, while Nexentis also holds solar investments via an RTB model.